MKC-1
MKC-1 is a pharmaceutical drug with 9 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 9 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
4
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
9 of 9 finished
0.0%
0 ended early
0
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Ro 31-7453 in Treating Patients With Locally Advanced or Metastatic Solid Tumor
Ro 31-7453 in Treating Patients With Metastatic Solid Tumors
Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer
A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer
Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer
Clinical Trials (9)
Ro 31-7453 in Treating Patients With Locally Advanced or Metastatic Solid Tumor
Ro 31-7453 in Treating Patients With Metastatic Solid Tumors
Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer
A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer
Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer
Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer
Phase 1 Study of MKC-1 in Patients With Advanced Cancer
A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9